Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) on May 7, 2025. The registrant is incorporated in Delaware and its common stock (CYCC) and preferred stock (CYCCP) trade on The Nasdaq Capital Market. The report details a corporate action regarding a reverse stock split.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure change rather than financial performance results.
Material Changes
- Reverse Stock Split: The Company implemented a one-for-sixteen reverse stock split via an amendment to its Certificate of Incorporation.
- Effective Date: The split became effective on May 12, 2025, with trading on a split-adjusted basis commencing at market open on that date.
- Purpose: The Board of Directors approved the amendment primarily to meet the minimum bid price requirements of The Nasdaq Capital Market.
- Shareholder Approval: Stockholders approved the amendment at a special meeting held on February 6, 2025.
- Fractional Shares: No fractional shares will be issued. Entitlements of one-half or more of a fractional share are rounded up; those less than one-half are rounded down.
- Securities Adjustment: All outstanding options, warrants, and convertible securities were adjusted in accordance with their governing terms.
- Identifiers: The trading symbol remains "CYCC," but the Company was assigned a new CUSIP number (23254L884).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of maintaining Nasdaq listing compliance. The primary contingency addressed is the adjustment of outstanding equity instruments to align with the new share count.
Investor Verification Checklist
- Verify the new CUSIP number (23254L884) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-May 12, 2025.
- Review the treatment of fractional shares to ensure rounding was applied correctly (up for ≥0.5, down for <0.5).
- Check the adjustment terms for any outstanding options or warrants held.
- Monitor the stock price to ensure it meets the Nasdaq Capital Market minimum bid price requirement following the split.